8-K: Xtant Medical Extends Promissory Note, Payment Dates

Xtant Medical Holdings, Inc. announced an extension of the maturity date for an $8.2 million promissory note and a $1.742 million purchase price adjustment payment related to recent divestitures.

Summary

• Xtant Medical Holdings, Inc. (the "Company") previously completed the sale of its Coflex and CoFix products to Companion Spine, LLC and Companion Spine SAS on December 1, 2025, for a total purchase price of $17.5 million.
• An $8.2 million unsecured promissory note (the "Note") from Companion Spine was issued to the Company as part of the Coflex/CoFix Divestiture, originally scheduled to mature on January 15, 2026.
• The Company also completed the sale of Paradigm Spine GmbH to Companion Spine SAS on December 1, 2025, for $1.7 million, subject to adjustments.
• On January 15, 2026, the Company and Companion Spine amended the Note to extend its maturity date from January 15, 2026, to January 31, 2026.
• The purchase agreement for the sale of Paradigm Spine GmbH was also amended to change the timing for payment of the $1,742,000 estimated positive purchase price adjustment from January 15, 2026, to January 31, 2026.

Sentiment

Score: 4

Explanation: The extension of payment dates for significant amounts, while not a default, indicates a delay in expected cash inflows, which is generally viewed negatively by investors as it impacts liquidity and introduces uncertainty.

Negatives

• The Company will experience a delay in receiving $8.2 million from the promissory note, which was originally due on January 15, 2026.
• The payment of a $1,742,000 estimated positive purchase price adjustment for Paradigm Spine GmbH has also been delayed from January 15, 2026, to January 31, 2026.

Risks

• Potential for further delays in receiving the $8.2 million promissory note payment and the $1,742,000 purchase price adjustment from Companion Spine.
• Risk of non-payment or default by Companion Spine, although the current amendment is an extension, not a default.

Future Outlook

The Company expects to receive the $8.2 million from the promissory note and the $1,742,000 estimated positive purchase price adjustment by January 31, 2026, following the amendments.

Industry Context

This announcement reflects ongoing strategic adjustments within the medical device sector, specifically concerning spine products. Divestitures like these often indicate a company's effort to streamline operations, focus on core competencies, or improve financial liquidity. The delay in payment, however, could signal potential liquidity challenges for the acquiring entity, Companion Spine, or a renegotiation of terms common in complex M&A transactions.

Stakeholder Impact

• Shareholders may view the delay in cash receipts negatively, potentially impacting investor confidence and the company's perceived liquidity.
• The company's short-term cash flow projections will need to be adjusted to reflect the delayed payments.

Next Steps

• Monitor for the receipt of the $8.2 million promissory note payment by January 31, 2026.
• Monitor for the receipt of the $1,742,000 estimated positive purchase price adjustment by January 31, 2026.

Key Dates

Recommendation

While the company secured an extension rather than a default, the delay in receiving over $9.9 million in expected payments introduces uncertainty regarding cash flow and the counterparty's financial health. Investors should hold and monitor the situation closely for the updated payment date, as continued delays or non-payment could significantly impact the company's financial position.

Keywords

Xtant Medical, XTNT, SEC filing, 8-K, promissory note, divestiture, Coflex, CoFix, Paradigm Spine, Companion Spine, payment extension, medical devices, spine products, asset sale